SCHEMBL17200540

SCHEMBL17200540

O=C(O)CC1CCc2cc(-c3ccc(NC(=O)Nc4cccc(S(F)(F)(F)(F)F)c4)cc3)ccc2C1

nearest known ligand 0.78

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.78
ITGB3 P05106 2/20 0.48
ITGA2B P08514 2/20 0.48
MCHR1 Q99705 8/20 0.46
DCUN1D1 Q96GG9 1/20 0.43
CNR1 P21554 2/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
MGLL Q99685 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14060436 0.88 DGAT1 (1.00) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200609 0.87 DGAT1 (0.82) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200553 0.85 DGAT1 (0.82) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200593 0.85 DGAT1 (0.82) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200585 0.85 DGAT1 (0.78) DGAT1ITGB3ITGA2BMCHR1MEN1
SCHEMBL14059721 0.85 DGAT1 (0.78) DGAT1ITGB3ITGA2BMCHR1MEN1
SCHEMBL17200564 0.84 DGAT1 (0.83) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200572 0.83 DGAT1 (0.75) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200536 0.83 DGAT1 (0.78) DGAT1ITGB3ITGA2BMCHR1CNR1
SCHEMBL17200615 0.83 DGAT1 (0.78) DGAT1ITGB3ITGA2BMCHR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 EP claimed
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 EP disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors DGAT1, DGAT2, LCAT DGAT1 1/4885ITGB3 3896/4885ITGA2B 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.